AI-Driven Early Detection of Skin Cancer

NCT07144306 · tracked via the Priya Life Science UK tracker

Sponsor

Nuvana Healthcare LTD

Phase

Observational

Started

2025-10-01

Last updated

2025-09-26

Condition(s) studied

Skin Cancer Melanoma

Investigational drug(s) / intervention(s)

Smartphone-based AI skin lesion analysis (NuvanaDx platform).

Smartphone-based AI skin lesion analysis (NuvanaDx platform).: Smartphone-based AI skin lesion analysis (NuvanaDx platform).

Study summary

This study evaluates the feasibility and accuracy of an AI-powered mobile platform (NuvanaDx) for early detection of skin cancer, including melanoma, using smartphone-based imaging. The platform is designed to improve access to early diagnosis, reduce waiting times, and support triage into appropriate care pathways.

Eligibility

Sex

ALL

Min age

18 Months

Max age

—

Healthy volunteers

Accepted

Inclusion Criteria: Adults (≥18 years) presenting with skin lesions suspicious for malignancy. Ability to provide informed consent. Exclusion Criteria: Inability to provide informed consent. Poor-quality images unsuitable for AI analysis.

Primary outcome measure(s)

Diagnostic Accuracy of AI tool compared with dermatologist-confirmed diagnosis — Time Frame: Up to 12 months
Diagnostic Accuracy of AI tool compared with dermatologist-confirmed diagnosis Time Frame: Up to 12 months Measure: Sensitivity, specificity, and predictive values

Trial sites (1)

Facility	City	Region	Status
Nuvana Healthcare Ltd	London	United Kingdom	Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07144306 on ClinicalTrials.gov ↗ ← All trials in the UK